Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Akari Therapeutics Plc · 10-Q · Q2 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

We are a smaller reporting company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information required under this item. 28 Item